These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 36821822)

  • 1. E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
    Michaelides IN; Collie GW
    J Med Chem; 2023 Mar; 66(5):3173-3194. PubMed ID: 36821822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
    Rothweiler EM; Brennan PE; Huber KVM
    Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
    Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
    Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
    Cowan AD; Ciulli A
    Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAC-tics for Leveraging Proximity Biology in Drug Discovery.
    Nalawansha DA; Mangano K; den Besten W; Potts PR
    Chembiochem; 2024 Feb; 25(4):e202300712. PubMed ID: 38015747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues.
    Ramachandran S; Ciulli A
    Curr Opin Struct Biol; 2021 Apr; 67():110-119. PubMed ID: 33271439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
    Shah Zaib Saleem R; Schwalm MP; Knapp S
    Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
    Dobrodziej J; Dong H; Zimmermann K; Hickey CM
    Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
    Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
    ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of Aberrant E3 Ligases Implicated in Alzheimer's Disease and Development of Chemical Tools to Modulate Their Function.
    Potjewyd FM; Axtman AD
    Front Cell Neurosci; 2021; 15():768655. PubMed ID: 34867205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation.
    Sobierajski T; Małolepsza J; Pichlak M; Gendaszewska-Darmach E; Błażewska KM
    Drug Discov Today; 2024 Jul; 29(7):104032. PubMed ID: 38789027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
    Nalawansha DA; Crews CM
    Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
    Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
    Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.